Search

Displaying results 5241 - 5250 of 8575 in total
  1. Drug

    Cytochlor

    go.drugbank.com/drugs/DB12383
    Investigational

    Cytochlor has been used in trials studying the treatment of Head and Neck Cancer and Brain and Central Nervous System Tumors.

  2. Drug

    LY-2452473

    go.drugbank.com/drugs/DB12573
    Investigational

    Ly2452473 has been investigated for the treatment of Erectile Dysfunction.

  3. Drug

    AMG-208

    go.drugbank.com/drugs/DB08079
    Investigational

    AMG-208 has been used in trials studying the treatment of Cancer, Tumors, Oncology, Prostate Cancer, and Oncology Patients, among others.

  4. Drug

    Metiamide

    go.drugbank.com/drugs/DB08805
    Experimental

    It was an intermediate product on the path to developing cimetidine.

  5. Drug

    Obatoclax

    go.drugbank.com/drugs/DB12191
    Investigational

    Obatoclax has been used in trials studying the treatment of AML, Leukemia, Myelofibrosis, Hodgkin's Lymphoma, and Mantle-Cell Lymphoma, among others.

  6. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    Orally absorbed GFT14 has absolutely no structural link with current treatments for dyslipidemia (statin or fibrate based). … GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.

  7. Drug

    Niflumic acid

    go.drugbank.com/drugs/DB04552
    Investigational

    Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.

  8. Drug

    Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells

    go.drugbank.com/drugs/DB28348
    Approved

    [L54146] Zemcelpro was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation following myeloablative conditioning

  9. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials. … Unlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer disease-modifying effects in patients with AD.

  10. Drug

    SGX-523

    go.drugbank.com/drugs/DB06314
    Investigational

    A MET receptor tyrosine kinase inhibitor.